It’s a nail-biting time for UK-based biotech Verona Pharma plc. Over 15 years since its founding, Verona will soon deliver results of a second Phase III trial of chronic obstructive pulmonary disease (COPD) hopeful ensifentrine. If it replicates the strongly positive efficacy and safety data seen in a first study, the company has a blockbuster in its hands, according to analysts. If not, Verona's survival may be at stake.
This binary outlook is typical for an asset-focused biotech. What’s less ordinary about Nasdaq-listed Verona is that it’s gearing up...